Last reviewed · How we verify
OligoG Dry powder for inhalation
OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways.
OligoG Dry Powder for Inhalation is an investigational inhaled therapeutic developed by AlgiPharma AS for cystic fibrosis (CF), targeting the underlying pathophysiology of CF lung disease through a novel mechanism. The drug is composed of oligosaccharides derived from alginate and is designed to modulate biofilm formation and reduce bacterial adherence in the CF airway. Clinical development included four Phase 2 trials enrolling 105 patients total, with completed studies in CF populations including those with Burkholderia spp. infection and lung deposition characterization via radiolabeled formulation. The program has been discontinued, with no regulatory approvals achieved in any jurisdiction. The discontinuation reflects challenges in demonstrating clinical efficacy or commercial viability in the competitive CF therapeutic landscape, where approved agents like ivacaftor, lumacaftor, and tezacaftor dominate. No commercial revenue was generated, and the asset remains in the public domain without active development.
At a glance
| Generic name | OligoG Dry powder for inhalation |
|---|---|
| Also known as | Placebo dry powder for inhalation |
| Sponsor | AlgiPharma AS |
| Drug class | Anti-biofilm agent; inhaled oligosaccharide therapeutic |
| Target | Bacterial biofilm matrix and adhesion mechanisms in cystic fibrosis airways |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
OligoG is derived from alginate oligosaccharides and functions as a biofilm disruptor in the cystic fibrosis lung microenvironment. In CF, chronic bacterial infections—particularly Pseudomonas aeruginosa and Burkholderia species—form dense biofilms that are resistant to antibiotics and immune clearance, driving progressive lung damage. OligoG is hypothesized to interfere with biofilm matrix structure and bacterial adhesion mechanisms, potentially enhancing antibiotic penetration and immune recognition. By targeting the physical architecture of biofilms rather than bacterial viability directly, OligoG represents a mechanistically distinct approach to CF airway infection management, complementary to existing antimicrobial and CFTR modulator therapies.
Approved indications
Pipeline indications
- Cystic Fibrosis (general) — Phase 2
- Cystic Fibrosis with Burkholderia spp. Infection — Phase 2
- Lung Deposition Characterization in Cystic Fibrosis — Phase 2
Common side effects
Key clinical trials
- A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis (PHASE2)
- A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (PHASE2, PHASE3)
- A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection (PHASE2)
- A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (PHASE2)
- A Study to Investigate Lung Deposition of Radiolabelled OligoG (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OligoG Dry powder for inhalation CI brief — competitive landscape report
- OligoG Dry powder for inhalation updates RSS · CI watch RSS
- AlgiPharma AS portfolio CI